Last reviewed · How we verify
NCT03959436
Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery
trial testing Carbetocin in Carbetocin in 612 participants. Completed in 16 March 2018.
16 March 2018
Quick facts
| Lead sponsor | Maisonneuve-Rosemont Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 612 |
| Start date | 29 March 2017 |
| Primary completion | 16 March 2018 |
| Estimated completion | 16 March 2018 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Carbetocin (CARBETOCIN) — full drug profile →
Conditions studied
- Carbetocin — all drugs for Carbetocin →
- Cesarean Section Complications — all drugs for Cesarean Section Complications →
- Uterotonics — all drugs for Uterotonics →
- Uterine Atony With Hemorrhage — all drugs for Uterine Atony With Hemorrhage →
Sponsor
Maisonneuve-Rosemont Hospital
Who can join
Eligibility, female only, with Carbetocin or Cesarean Section Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Carbetocin (Duratocin®) is a long-acting form of oxytocin, with a half-life almost 10 times longer. Studies have demonstrated that carbetocin diminishes the need for secondary uterotonic agents compared to oxytocin for cesarean delivery (CD). Despite certain Canadian guidelines recommending its use for elective CD, several Canadian centers and other countries have not adopted carbetocin. The purpose of this study is to prospectively gather electronic data on all CDs over a one year period, elective and emergent, in a single institution, and to evaluate the efficacy and other clinical outcomes when carbetocin is used as a first line uterotonic for all CDs. A database using Microsoft Dynamics CRM is available on smart phones and tablets. Data regarding additional uterotonic use and impact of carbetocin use during CD on intra and postoperative outcomes are gathered and analyzed. The primary outcome is the use of additional uterotonics in this population compared to that described in the literature for oxytocin as the primary uterotonic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03959436
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Carbetocin
Trials testing the same drug.
- NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
- NCT06946589 — Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section · Phase 4 · not yet recruiting
- NCT06776926 — Timing of Carbetocin Administration in Postpartum Hemorrhage · NA · completed
- NCT06692621 — Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain · completed
- NCT07380529 — Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesar · NA · completed
Other Maisonneuve-Rosemont Hospital trials
Trials by the same sponsor.
- NCT06332443 — Randomized, Controlled Trial Comparing the Effectiveness of Sedation-Epidural Anesthesia to Spinal Anesthesia in Outpati · NA · unknown
- NCT05217966 — Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS) · NA · recruiting
- NCT05075226 — Visual Outcomes of Vivity in Patients With Well Controlled Glaucoma · unknown
- NCT03697967 — Supine vs Prone Position During Delayed Cord Clamping · NA · completed
- NCT04138082 — Impact of Noise on Anesthesiologists' and Trainees' Situational Awareness in a High Fidelity Simulation Environment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03959436 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maisonneuve-Rosemont Hospital
- Last refreshed: 29 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03959436.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing